Biogen BIIB Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 301.9%-0.3pp | 302.3%-2.4pp | 304.7%-5.4pp | 310%-22.7pp | |
| Net margin | 59.9%+2.2pp | 57.7%-26.4pp | 84.1%-6.2pp | 90.4%+22.0pp | |
| Returns | |||||
| Return on equity | 35.3%-1.2pp | 36.5%-27.7pp | 64.2%-17.0pp | 81.2%+8.9pp | |
| Return on invested capital | 32%+0.6pp | 31.3%-20.8pp | 52.2%-12.9pp | 65.1%-1.0pp | |
| Efficiency | |||||
| Asset turnover | 1.4×0.0× | 1.4×-0.1× | 1.6×-0.2× | 1.7×-0.1× | |
| Liquidity | |||||
| Current ratio | 9.3×+2.3× | 7×-3.2× | 10.2×+0.8× | 9.4×+1.6× | |
| Leverage | |||||
| Debt-to-equity | 1.4×-0.2× | 1.6×-0.4× | 1.9×-0.2× | 2.2×-0.6× | |
| Net debt / EBITDA | 4.6×-3.2× | 7.8×+0.5× | 7.3×+3.3× | 4×-2.9× | |
| Per Share | |||||
| Book value per share | $483.91+10.1% | $439.72+11.0% | $396.12+17.4% | $337.37+18.5% | |
| Valuation | |||||
| Market capitalization | $84.89B-26.6% | $115.61B-25.9% | $156.12B+12.0% | $139.44B-17.4% | |
| Price / earnings | 57.6×-29.5× | 87.1×+1.1× | 86.1×+23.6× | 62.5×-27.2× | |
| Price / sales | 8.5×-3.4× | 12×-3.7× | 15.6×+2.3× | 13.3×-1.2× | |
| Price / book | 4.8×-2.5× | 7.2×-3.6× | 10.9×-0.4× | 11.3×-4.5× | |
| EV / EBITDA | 36.1×-21.7× | 57.8×-5.2× | 63×+23.5× | 39.5×-19.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Biogen's profit margins?
- Biogen (BIIB) runs a 75.5% gross margin and a 22.9% operating margin, with a 14.3% net margin.
- Where do Biogen's ratios come from?
- Every ratio is computed from Biogen's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
